Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert

Two year result of topography-guided photorefractive keratectomy with cross-linking for keratoconus with high speed laser

Search Title by author or title

Session Details

Session Title: Cross-Linking Protocols

Session Date/Time: Monday 24/09/2018 | 14:00-16:00

Paper Time: 14:24

Venue: Room A3, Podium 3

First Author: : D.Lin CANADA

Co Author(s): :    S. Holland   M. Al Obthani   S. Arba Mosquera              

Abstract Details


Evaluation of Topography-guided Photorefractive Keratectomy (TG-PRK) for keratoconus (KC) with cross linking CXL) with Schwind Amaris 1050 (SA).


Laser Refractive Clinic


A retrospective consecutive series of keratoconic eyes were studied to evaluate the outcomes of Topographic Guided Photorefractive Keratectomy (TG-PRK) treatment with the Schwind Amaris 1050 Excimer laser and simultaneous corneal collagen cross-linking (CXL). Image capture with Sirius and CXL with a modified Dresden protocol. Pre-operative and post-operative uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), manifest refraction (MR) and topographic cylinder were analyzed. Cases with sufficient data at 24 months follow-up were included.


54 had sufficient data at 12 months for analysis. 27 of 54 (50%) showed UDVA ≥20/40 post-operatively. 22 (42%) had improved CDVA and 14 (26%) gained two or more lines (p=0.0003). No patient showed progression. Mean astigmatism was reduced from 3.14±1.56D to 2.10±1.67D (p<0.0001). Mean spherical equivalent was improved from -2.51±3.48D to -0.65±2.08D (p<0.0001).


Two year results of TG-PRK CXL with Schwind Amaris 1050 show efficacy and safety as treatment for eyes with keratoconus, with half of patients achieving 20/40 UDVA or better. 42% had improved CDVA with more than a quarter improving 2 or more lines providing an alternative to contact lens intolerant keratoconus patients.

Financial Disclosure:

... is employed by a for-profit company with an interest in the subject of the presentation, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented

Back to previous